/

ABUS

Arbutus Biopharma CorporationClosed

4.11−0.04 −0.96%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 4.12 +0.27%

Open

4.13

Prev close

4.15

Day range

4.054.16

52-week range

3.505.45

Volume

3.48M0.73×

Mkt cap

629.96M

P/E ttm

5.20

Fwd P/E

-24.87

EPS ttm

0.7900

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−24.59%

Price Chart

Yahoo Finance · delayed

ABUSOct 13, 2026O 4.13H 4.16L 4.05C 4.11−0.04 (−0.96%)Vol 3.48M

SMA 504.82
SMA 2004.53

1Y change −3.97% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ABUS Arbutus Biopharma Corporation · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.26%
1 month: −19.73%
3 months: −10.85%
6 months: −5.52%
Year to date: −14.55%
1 year: −3.97%

Valuation & ownership

Market cap: 629.96M
Enterprise value: 724.15M
P/E (ttm): 5.20
Forward P/E: -24.87
PEG ratio: —
Price / book: 3.14
Price / sales (ttm): 3.47
EV / EBITDA: 4.91
EPS (ttm): 0.7900
EPS (forward): -0.1653
Beta (5y monthly): 0.76
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 153.28M
Float: 150.53M
Short % of float: 38.47%
Short ratio (days): 5.03
Held by insiders: 15.92%
Held by institutions: 66.92%
Avg volume (3m): 4.78M
50-day average: 4.83
200-day average: 4.53
52-week change: −3.97%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 27.6
vs 50-day SMA: −14.78%
vs 200-day SMA: −9.21%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.10%
Realised vol (20d, ann.): 37.6%
From 52-week high: −24.59%
From 52-week low: +17.43%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

5.37

+30.68% implied

Low 5.37Median 5.37High 5.37

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

DES

About Arbutus Biopharma Corporation

Yahoo Finance profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 19
Headquarters: Warminster, PA, United States
Website: arbutusbio.com
Officers: Ms. Lindsay Androski J.D., M.B.A. President, CEO & Chairman
Mr. Tuan Nguyen Chief Financial Officer
Mr. Andrew J. Sung General Counsel

SEAS

Seasonality · ABUS

2007–2026 · monthly returns

Strongest month Jul +13.72%Weakest month Oct −6.77%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-14.1	12.8	-3.4	-6.7	8.6	5.3	-9.6	17.1	-5.9	-14.0			−14.6%
2025	1.8	3.6	1.2	1.7	-5.4	-8.0	6.1	13.1	22.4	4.2	-6.8	9.1	+47.1%
2024	-5.2	18.1	-7.9	5.8	23.1	-8.0	22.0	2.7	-0.5	0.0	-10.1	-5.5	+30.8%
2023	29.2	-7.6	9.0	-17.2	-0.8	-7.6	-5.7	-6.5	0.0	-9.9	12.0	22.0	+7.3%
2022	-27.8	13.9	-6.9	-21.8	4.3	11.5	-14.8	-3.9	-14.0	22.5	0.4	-0.9	−40.1%
2021	6.5	-0.8	-11.2	4.2	-18.4	7.1	-11.2	27.5	25.1	-6.1	-20.6	21.6	+9.6%
2020	-6.1	11.9	-65.4	14.9	87.1	-16.1	109.3	-23.6	7.6	-9.9	60.6	-21.6	+27.7%
2019	-3.7	19.0	-18.5	-24.9	-32.3	14.3	-14.4	-23.0	11.7	-7.2	17.6	66.5	−27.4%
2018	1.0	6.9	-8.3	14.0	2.6	24.8	52.1	-18.0	3.8	-55.1	2.8	-12.2	−24.2%
2017	8.2	1.1	21.3	4.6	0.0	5.9	-4.2	21.7	47.6	-8.9	0.0	-10.6	+106.1%
2016	-29.4	0.6	30.7	19.9	-16.4	-15.9	17.5	-6.8	-9.7	-8.4	-15.9	-7.5	−44.9%
2015	69.0	-29.1	-3.9	-11.4	-9.7	-15.1	-8.7	-34.3	-14.3	-9.7	1.5	-20.3	−70.6%
2014	75.2	47.9	4.1	-38.2	-4.4	2.8	-1.9	67.1	-1.2	-21.1	-9.0	-0.2	+90.1%
2013	-5.2	-6.0	6.6	1.3	4.8	-6.0	16.2	-0.5	28.0	28.8	-8.9	-2.2	+60.7%
2012	38.7	23.1	1.6	-6.9	-11.2	-1.9	66.4	-4.8	8.7	11.3	23.5	-0.6	+230.7%
2011	26.0	-16.4	-36.4	-4.4	10.6	-24.6	-4.0	-20.7	-5.8	-5.6	0.0	-11.8	−68.1%
2010	-18.5	-2.7	21.9	0.0	37.1	7.4	22.1	-5.0	-21.1	0.0	-15.5	-7.3	+2.2%
2009	82.8	-1.9	3.8	29.6	62.9	-14.9	5.2	-3.9	12.2	-18.2	5.6	-3.2	+217.2%
2008	3.3	-1.1	24.7	-3.4	25.9	-30.5	-5.1	-5.4	-25.0	-48.5	-14.7	0.0	−68.1%
2007								2.7	14.9	13.0	-18.2	-24.8	−18.0%

INSD

Insider Activity · ABUS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 17, 2026	Beardsley Robert ADirector	Conversion of Exercise of derivative security at price 3.20 - 4.24 per share.	131.3K	$502.22K
Sep 17, 2026	Sawhney Roger M.D.Director	Conversion of Exercise of derivative security at price 3.34 - 4.24 per share.	131.3K	$509.57K
Sep 17, 2026	Androski Lindsay J.D.Chief Executive Officer	Conversion of Exercise of derivative security at price 3.20 - 4.39 per share.	126.9K	$418.41K
Sep 17, 2026	Nguyen TuanChief Financial Officer	Conversion of Exercise of derivative security at price 3.49 - 4.39 per share.	293.1K	$1.05M
Feb 1, 2026	Androski Lindsay J.D.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	28K	—
Feb 1, 2026	Nguyen TuanChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	73.5K	—
Feb 13, 2025	Naftzger J ChristopherGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	54.3K	—
Feb 13, 2025	Hastings David CChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	90.1K	—
Feb 13, 2025	Sims KarenOfficer	Stock Award(Grant) at price 0.00 per share.	49.3K	—
Feb 3, 2025	Naftzger J ChristopherGeneral Counsel	Sale at price 3.28 per share.	11.3K	$37.21K
Feb 3, 2025	Hastings David CChief Financial Officer	Sale at price 3.28 per share.	22.2K	$72.83K
Feb 3, 2025	Sims KarenOfficer	Sale at price 3.28 per share.	19.3K	$63.52K

ABUS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ABUS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arbutus Biopharma Corporation

Seasonality · ABUS

Insider Activity · ABUS

Congress Trades · ABUS

Investors Holding ABUS

Investors Holding ABUS

Congress Trades · ABUS

Insider Activity · ABUS

Seasonality · ABUS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arbutus Biopharma Corporation

Financial Snapshot

Earnings & Dividends

News